Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia

NCT00002812 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2078

Last updated 2013-08-26

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more cancer cells.

PURPOSE: Randomized phase III trial to compare the effectiveness of standard combination chemotherapy treatment with more intensive combination chemotherapy in treating children with acute lymphocytic leukemia.

Conditions

Interventions

DRUG

asparaginase

Given IV

DRUG

cyclophosphamide

Given IV

DRUG

cytarabine

Given IV

DRUG

daunorubicin hydrochloride

Given IV

DRUG

dexamethasone

Given IV

DRUG

doxorubicin hydrochloride

Given IV

DRUG

idarubicin

Given IV

DRUG

mercaptopurine

Given IV

DRUG

methotrexate

Given PO

DRUG

pegaspargase

Given IV

DRUG

prednisone

Given PO

DRUG

thioguanine

Given IV

DRUG

vincristine sulfate

Given IV

RADIATION

radiation therapy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH
  • Children's Oncology Group

    lead NETWORK

Principal Investigators

  • Nita L. Seibel, MD · Children's National Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-09-30
Primary Completion
2006-03-31

Countries

  • United States
  • Australia
  • Canada

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002812 on ClinicalTrials.gov